Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. (NASDAQ:LEXX) is a pioneering company in the field of drug delivery technology. The company has developed and patented a unique drug delivery platform known as DehydraTECH™, which enhances the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. This technology is notable for significantly improving bio-absorption rates, reducing the onset time of drugs, and masking unpleasant tastes.
DehydraTECH™ has demonstrated remarkable efficacy in enhancing the bio-absorption of cannabinoids and nicotine, increasing their uptake by 5-10 times, and in some cases, by as much as 27 times compared to traditional formulations. This technology also shows potential in improving the delivery of certain drugs through the blood-brain barrier, making it particularly valuable for drugs targeting the central nervous system.
The company operates four key segments: Intellectual Property Licensing, B2B Production, Research and Development, and Corporate. Intellectual Property Licensing is the primary revenue generator for Lexaria, leveraging its robust portfolio of 43 granted patents and numerous pending patents worldwide.
Lexaria's recent endeavors include a series of human and animal studies focused on the application of DehydraTECH™ in enhancing the delivery and efficacy of GLP-1 drugs. These drugs, such as semaglutide and tirzepatide, are primarily used for treating diabetes and promoting weight loss. The company has partnered with the National Research Council of Canada (NRC) to investigate the molecular characteristics and performance of DehydraTECH-processed GLP-1 drugs.
The latest human pilot studies have shown promising results, including higher drug delivery and better blood glucose control with fewer side effects. The company is also exploring the use of DehydraTECH™ for other APIs like cannabidiol (CBD), with applications in treating hypertension and epilepsy.
Recent financial activities include a warrant exercise agreement, raising approximately $4.7 million, which bolsters Lexaria's operational runway into 2025. This financial stability allows the company to pursue its aggressive research and development plans.
Lexaria's innovative approach and continuous research efforts position it as a significant player in the drug delivery technology sector, with the potential to form strategic partnerships with leading pharmaceutical companies.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has entered into agreements with Altria to provide DehydraTECH powder-based nicotine formulations for evaluation. These agreements will be effective until March 31, 2023. Lexaria's DehydraTECH technology enhances the bio-absorption of active pharmaceutical ingredients, improving oral delivery by 5-10 times and reducing onset times from 1-2 hours to minutes. The company holds 24 patents and has over 50 pending worldwide. For further details, visit Lexaria's website.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has launched its epilepsy research program, EPIL-A21-1, which will evaluate the effectiveness of DehydraTECH-CBD against Epidiolex, the first FDA-approved CBD treatment for seizures. The necessary test articles have been prepared and delivered to a third-party lab for dosing. Research phases will include acute and chronic seizure models, starting in May/June, with results expected by Q3 2022. The program is fully funded through existing resources, underscoring Lexaria's commitment to advancing its drug delivery technology.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the granting of its 24th patent, titled "Compositions Infused with Nicotine Compounds and Methods of Use Thereof," enhancing its global intellectual property portfolio. This Australian patent allows the use of DehydraTECH technology for various nicotine forms, potentially increasing product value. Previous studies show DehydraTECH delivers nicotine significantly faster than conventional methods. Additionally, the company issued 36,700 stock options to staff at an exercise price of $3.39.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) reported significant findings from an animal study evaluating its DehydraTECH formulation of sildenafil, showing a 74% increase in drug delivery at 4 minutes compared to a generic control. The study indicated a 70% higher maximum concentration (Cmax) and a 37% improvement in total delivery (AUC). Results showed potential for developing faster-acting sildenafil formulations. However, improvements did not achieve statistical significance, necessitating further studies.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) shared an annual letter from CEO Chris Bunka, highlighting successes and strategic directions for the company. The focus remains on advancing the DehydraTECH drug delivery technology, aimed at overcoming industry inertia and regulatory challenges. Lexaria reported a growth in shareholder base, with average shares owned by NOBO shareholders increasing by 216% in 2021. The company's institutional ownership has also surged, ranging between 9% and 16%. The aim is to leverage this momentum for potential regulatory and commercial success in 2022.
Lexaria Bioscience Corp. (NASDAQ:LEXX) recently highlighted a study demonstrating cannabinoids' potential to inhibit SARS-CoV-2 infection.
Dr. Richard van Breeman noted that oral delivery of cannabinoids is recommended over smoking or vaping for effectiveness.
Lexaria's DehydraTECH™ technology enhances cannabinoid delivery, with applications in therapeutic formulations.
The study found cannabinoid acids can block cellular entry of the virus, presenting significant implications for treatment strategies.
Lexaria holds a strong patent portfolio, with ongoing research into pharmaceutical applications.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has received early Independent Review Board approval for its DehydraTECH-CBD hypertension study, HYPER-H21-4, scheduled to begin dosing by April 2022. This study, funded through existing cash resources, aims to assess the treatment's efficacy in reducing blood pressure among 60 volunteers aged 45-70. The $28 billion hypertension market presents significant growth potential, especially in emerging economies. With a comprehensive analysis including blood pressure monitoring and brain imaging, Lexaria seeks to validate DehydraTECH-CBD as a promising anti-hypertensive therapy.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced a media and digital marketing agreement with SRAX to enhance investor engagement over the next year. This follows substantial progress made by the company in 2021, with plans for an extensive 2022 including a human hypertension study and a nicotine study. Lexaria will issue 224,299 restricted shares valued at $1.2 million to SRAX for its services. The agreement aims to maximize visibility through a sustained marketing campaign, leveraging SRAX's analytical capabilities.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announces the near completion of its human clinical study HYPER-H21-3, which is exploring the effects of DehydraTECH-CBD on acute pulmonary hypertension. The study involved a placebo-controlled trial with 16 volunteers receiving a 300mg dose of DehydraTECH-CBD. Blood samples are currently being analyzed, with results expected soon. This research aims to contribute to the understanding of DehydraTECH-CBD as a treatment for hypertension and will be submitted to the FDA as part of their investigational drug research program.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has released follow-up results from clinical study HYPER-H21-2, indicating that its DehydraTECH-CBD significantly reduces arterial stiffness after just one day of dosing. This finding suggests potential applications beyond hypertension, including in cardiovascular health. Notably, pulse wave velocity (PWV) was measured at 8.1 ± 0.3 m/s for DehydraTECH-CBD versus 8.3 ± 0.3 m/s for placebo, with all comparisons yielding statistically significant results (p < 0.01). Future studies, including the upcoming HYPER-H21-4, will explore these findings further.
FAQ
What is the current stock price of Lexaria Bioscience (LEXX)?
What is the market cap of Lexaria Bioscience (LEXX)?
What is Lexaria Bioscience Corp. known for?
How does DehydraTECH™ improve drug delivery?
What are the main business segments of Lexaria?
What recent achievements has Lexaria accomplished?
What are some key applications of DehydraTECH™?
How many patents does Lexaria hold?
What partnerships has Lexaria recently engaged in?
What financial activities has Lexaria recently undertaken?
How does DehydraTECH™ benefit centrally active compounds?
Where can I find more information about Lexaria?
